Baseline clinical characteristics.

<p>Baseline clinical characteristics.</p

Effectiveness and disease activity evaluation in the enrolled patients.

<p>This Figure shows: A) and B) the progressive reduction of both DAS28 and SDAI values; C) the disease activity at the first observation and after 12 months of follow up, respectively; E) the EULAR response criteria after 12 months of follow up.</p

Predictive factors of new CVEs onset.

<p>Predictive factors of new CVEs onset.</p

Traditional CV risk factors, CVEs and subclinical atherosclerosis, comparison between time 0 and 12 month.

<p>This Figure shows: A), B) and C) the increased percentages of patients affected by SAH, MS and T2D (p<0.00001 for each comparison), after 12 months of follow up. D) and E) After 12 months, we observed an increased percentage of patients experienced new CVEs and developed subclinical atherosclerosis, respectively (p<0.00001 for each comparison).</p

Therapeutic strategies of the enrolled patients at the first visit.

<p>Therapeutic strategies of the enrolled patients at the first visit.</p

Demographic features in the subset of patients with CVEs and subclinical atherosclerosis at the first observation and after 12 months of follow up.

<p>Demographic features in the subset of patients with CVEs and subclinical atherosclerosis at the first observation and after 12 months of follow up.</p

Evaluation of pro-inflammatory markers.

<p>This Figure shows: A) and B) the progressive reduction of the serum mean levels of ESR; C) and D) the progressive reduction of the serum mean levels of CRP, during the follow up.</p

Comparison of lipid profile between time 0 and 12 month.

<p>This Figure shows: A) and B) the mean serum levels of total cholesterol, HDL, LDL triglycerides at the first observation and after 12 months of follow up, respectively.</p